Chimerix Stock

Chimerix ROE

Delisted·Apr 17, 2025

The Return on Equity (ROE) of Chimerix (CMRX) as of Aug 26, 2026 is -72.64 %. In the previous year, Return on Equity (ROE) was -42.53 % — a change of 70.80% (lower).

ROE

-72.64 %

YoY

70.80%

Last updated:

In 2026, Chimerix's return on equity (ROE) was -72.64 %, a 70.80% increase from the -42.53 % ROE in the previous year.

The Chimerix ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
-32.00 USD
Jan 1, 2018
-39.12 USD
Jan 1, 2019
-157.93 USD
Jan 1, 2020
-57.41 USD
Jan 1, 2021
-374.78 USD
Jan 1, 2022
67.03 USD
Jan 1, 2023
-42.53 USD
Jan 1, 2024
-72.64 USD
The Chimerix ROE history
YEARROEYoY
-72.64 %+70.80%
-42.53 %-163.45%
67.03 %-117.88%
-374.78 %+552.80%
-57.41 %-63.65%
-157.93 %+303.74%
-39.12 %+22.23%
-32.00 %+15.72%
-27.66 %-20.96%
-34.99 %+62.01%
-21.60 %
Access this data via the Eulerpool API

Chimerix Stock analysis

What does Chimerix do? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix is one of the most popular companies on Eulerpool.

ROE Details

Decoding Chimerix's Return on Equity (ROE)

Chimerix's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Chimerix's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Chimerix's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Chimerix’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Chimerix stock

Return on Equity (ROE) of Chimerix is -72.64 % in 2026.

Return on Equity (ROE) of Chimerix changed from -42.53 % to -72.64 %, representing a 70.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Chimerix since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Chimerix with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Chimerix

All Key Metrics — Chimerix